Skip to main content
SpringerLink
Log in

Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Purpose

The aim of this study was to confirm the expression of high mobility group box 1 (HMGB1) in patients with epithelial ovarian cancer (EOC) and to evaluate the prognostic significance of HMGB1.

Methods

A total of 74 patients with EOC comprised our cohort. Retrospectively collected tissue microarray from EOC patients treated with debulking surgery followed by taxane and platinum chemotherapy were analyzed for evaluation of the prognostic significance of HMGB1. Expression of HMGB1 was assessed by immunohistochemistry.

Results

The positive staining was detected in 80 % of EOC patients and the rate of high HMGB1 expression was 42 %. In advanced stage, patients with high HMGB1 expression showed a poorer prognosis than low HMGB1 expression group [median progression-free survival (PFS), 10.8 vs. 21.7 months, P = 0.005]. High HMGB1 expression was an independent predictor for PFS (P = 0.024).

Conclusions

HMGB1 expression is expected as a promising biomarker for EOC and further studies are needed to assess potential roles in EOC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5–29

    Article  PubMed  Google Scholar 

  2. Malkasian GD Jr, Knapp RC, Lavin PT, Zurawski VR Jr, Podratz KC, Stanhope CR, Mortel R, Berek JS, Bast RC Jr, Ritts RE (1988) Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 159:341–346

    Article  PubMed  Google Scholar 

  3. Jacobs I, Bast RC Jr (1989) The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 4:1–12

    Article  PubMed  CAS  Google Scholar 

  4. Wang L, Kong B (2015) Analysis of the association of matrix metalloproteinase-1 gene promoter (rs1799750) polymorphism and risk of ovarian cancer. Int J Gynecol Cancer 25:961–967

    Article  PubMed  Google Scholar 

  5. Tiwari A, Ocon-Grove OM, Hadley JA, Giles JR, Johnson PA, Ramachandran R (2015) Expression of adiponectin and its receptors is altered in epithelial ovarian tumors and ascites-derived ovarian cancer cell lines. Int J Gynecol Cancer 25:399–406

    Article  PubMed  Google Scholar 

  6. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC (2002) Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287:1671–1679

    Article  PubMed  CAS  Google Scholar 

  7. Beyazit F, Ayhan S, Celik HT, Gungor T (2015) Assessment of serum angiotensin-converting enzyme in patients with epithelial ovarian cancer. Arch Gynecol Obstet 292:415–420

    Article  PubMed  CAS  Google Scholar 

  8. Wilailak S, Chan KK, Chen CA, Nam JH, Ochiai K, Aw TC, Sabaratnam S, Hebbar S, Sickan J, Schodin BA, Charakorn C, Sumpaico WW (2015) Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings. J Gynecol Oncol 26:46–53

    Article  PubMed Central  PubMed  Google Scholar 

  9. Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5:331–342

    Article  PubMed  CAS  Google Scholar 

  10. Mignogna MD, Fedele S, Lo Russo L, Lo Muzio L, Bucci E (2004) Immune activation and chronic inflammation as the cause of malignancy in oral lichen planus: is there any evidence? Oral Oncol 40:120–130

    Article  PubMed  Google Scholar 

  11. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ (2010) HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 28:367–388

    Article  PubMed  CAS  Google Scholar 

  12. Srinivasan M, Banerjee S, Palmer A, Zheng G, Chen A, Bosland MC, Kajdacsy-Balla A, Kalyanasundaram R, Munirathinam G (2014) HMGB1 in hormone-related cancer: a potential therapeutic target. Horm Cancer 5:127–139

    Article  PubMed  CAS  Google Scholar 

  13. Flohr AM, Rogalla P, Meiboom M, Borrmann L, Krohn M, Thode-Halle B, Bullerdiek J (2001) Variation of HMGB1 expression in breast cancer. Anticancer Res 21:3881–3885

    PubMed  CAS  Google Scholar 

  14. Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, Kuraoka K, Ito R, Yokozaki H, Yasui W (2002) Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 196:163–170

    Article  PubMed  CAS  Google Scholar 

  15. Kuniyasu H, Chihara Y, Takahashi T (2003) Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep 10:445–448

    PubMed  Google Scholar 

  16. Kuniyasu H, Chihara Y, Kondo H, Ohmori H, Ukai R (2003) Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer. Oncol Rep 10:1863–1868

    PubMed  CAS  Google Scholar 

  17. Takada M, Hirata K, Ajiki T, Suzuki Y, Kuroda Y (2004) Expression of receptor for advanced glycation end products (RAGE) and MMP-9 in human pancreatic cancer cells. Hepatogastroenterology 51:928–930

    PubMed  CAS  Google Scholar 

  18. Cheng BQ, Jia CQ, Liu CT, Lu XF, Zhong N, Zhang ZL, Fan W, Li YQ (2008) Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis 40:446–452

    Article  PubMed  CAS  Google Scholar 

  19. Chen J, Xi B, Zhao Y, Yu Y, Zhang J, Wang C (2012) High-mobility group protein B1 (HMGB1) is a novel biomarker for human ovarian cancer. Gynecol Oncol 126:109–117

    Article  PubMed  CAS  Google Scholar 

  20. Li Y, Tian J, Fu X, Chen Y, Zhang W, Yao H, Hao Q (2014) Serum high mobility group box protein 1 as a clinical marker for ovarian cancer. Neoplasma 61:579–584

    Article  PubMed  CAS  Google Scholar 

  21. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM, Schmidt AM (2000) Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405:354–360

    Article  PubMed  CAS  Google Scholar 

  22. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248–251

    Article  PubMed  CAS  Google Scholar 

  23. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30:1073–1081

    Article  PubMed  CAS  Google Scholar 

  24. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444

    Article  PubMed  CAS  Google Scholar 

  25. Bartling B, Hofmann HS, Weigle B, Silber RE, Simm A (2005) Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis 26:293–301

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by the Brain Korea (BK) 21 project for medical sciences, Yonsei University and by National Research Foundation of Korea Grant funded by the Korean Government (2009-0071158).

Author information

Author notes

    Authors and Affiliations

    1. Gynecologic Cancer Center, Department of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon, Republic of Korea

      Jiheum Paek

    2. Department of Obstetrics and Gynecology, Yonsei University Graduate School, Seoul, Republic of Korea

      Jiheum Paek

    3. Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea

      Maria Lee

    4. Department of Obstetrics and Gynecology, Institute of Women’s Life Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea

      Eun Ji Nam, Sang Wun Kim & Young Tae Kim

    Authors
    1. Jiheum Paek
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Maria Lee
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Eun Ji Nam
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Sang Wun Kim
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Young Tae Kim
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Young Tae Kim.

    Ethics declarations

    Conflict of interest

    All authors declare that there are no conflicts of interest.

    Additional information

    J. Paek and M. Lee contributed equally to this study.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Paek, J., Lee, M., Nam, E.J. et al. Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer. Arch Gynecol Obstet 293, 645–650 (2016). https://doi.org/10.1007/s00404-015-3864-1

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s00404-015-3864-1

    Keywords

    Search

    Navigation